Merck & Co., Inc. (MRK) Free Cash Flow (FCF): $12.36B
The free cash flow (FCF) for Merck & Co., Inc. (MRK) is $12.36B. It is below its 12-month average by 18.83% ($15.23B).
MRK Free Cash Flow (FCF) Chart
MRK Average Free Cash Flow (FCF) Chart
MRK Current vs Average Free Cash Flow (FCF) Chart
MRK Free Cash Flow (FCF) Metrics
FREE CASH FLOW (FCF)
$12.36B
FREE CASH FLOW (FCF) AVG TTM
$15.23B
FREE CASH FLOW (FCF) AVG 3Y
$13.58B
FREE CASH FLOW (FCF) AVG 5Y
$11.63B
FREE CASH FLOW (FCF) AVG 10Y
$10.24B
FREE CASH FLOW (FCF) AVG 15Y
$9.86B
FREE CASH FLOW (FCF) AVG 20Y
$8.80B
CURRENT VS TTM AVG
-18.83%
CURRENT VS 3Y AVG
-8.96%
CURRENT VS 5Y AVG
+6.26%
CURRENT VS 10Y AVG
+20.70%
CURRENT VS 15Y AVG
+25.31%
CURRENT VS 20Y AVG
+40.38%
FCF Analysis
Free Cash Flow (TTM)
$12.36B
FCF Yield
4.77%
Price/FCF
20.9
Formula: FCF = Operating Cash Flow - Capital Expenditures
Why FCF matters:
- Shows actual cash available (not accounting earnings)
- Funds dividends, buybacks, and debt reduction
- Less susceptible to accounting manipulation than net income
- Key metric for DCF valuation models
Merck & Co., Inc. Free Cash Flow (FCF) Formula & Definition
Free Cash Flow represents the cash a company generates after accounting for capital expenditures. It's the cash available for dividends, buybacks, debt reduction, or reinvestment.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Merck & Co., Inc. Free Cash Flow (FCF) FAQ
- What is the free cash flow (FCF) for Merck & Co., Inc. (MRK)?
- The free cash flow (FCF) for MRK stock is $12.36B.
- What is the TTM average free cash flow (FCF) for Merck & Co., Inc. (MRK)?
- The TTM average free cash flow (FCF) for MRK stock is $15.23B.
- What is the 3Y average free cash flow (FCF) for Merck & Co., Inc. (MRK)?
- The 3Y average free cash flow (FCF) for MRK stock is $13.58B.
- What is the 5Y average free cash flow (FCF) for Merck & Co., Inc. (MRK)?
- The 5Y average free cash flow (FCF) for MRK stock is $11.63B.
- What is the 10Y average free cash flow (FCF) for Merck & Co., Inc. (MRK)?
- The 10Y average free cash flow (FCF) for MRK stock is $10.24B.
- What is the 15Y average free cash flow (FCF) for Merck & Co., Inc. (MRK)?
- The 15Y average free cash flow (FCF) for MRK stock is $9.86B.
- What is the 20Y average free cash flow (FCF) for Merck & Co., Inc. (MRK)?
- The 20Y average free cash flow (FCF) for MRK stock is $8.80B.
Merck & Co., Inc. Free Cash Flow (FCF) History
| DATE | FREE CASH FLOW (FCF) |
|---|---|
| 2025-12-31 | $12.36B |
| 2024-12-31 | $18.10B |
| 2023-12-31 | $9.14B |
| 2022-12-31 | $14.71B |
| 2021-12-31 | $9.66B |
| 2020-12-31 | $5.82B |
| 2019-12-31 | $9.97B |
| 2018-12-31 | $8.31B |
| 2017-12-31 | $4.56B |
| 2016-12-31 | $8.76B |
| 2015-12-31 | $11.26B |
| 2014-12-31 | $6.54B |
| 2013-12-31 | $10.11B |
| 2012-12-31 | $8.07B |
| 2011-12-31 | $10.66B |
| 2010-12-31 | $9.79B |
| 2009-12-31 | $1.93B |
| 2008-12-31 | $7.17B |
| 2007-12-31 | $5.99B |
| 2006-12-31 | $5.79B |
| 2005-12-31 | $6.21B |
| 2004-12-31 | $7.07B |
| 2003-12-31 | $7.95B |
| 2002-12-31 | $7.16B |
| 2001-12-31 | $6.36B |
| 2000-12-31 | $4.96B |
| 1999-12-31 | $3.57B |
| 1998-12-31 | $3.35B |
| 1997-12-31 | $4.87B |
| 1996-12-31 | $4.23B |
Related Metrics
About Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert Davis